Zapping the brain to zap migraines: new study tests 20-Day stimulation
NCT ID NCT05769348
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if a gentle, non-invasive brain stimulation (tDCS) given for 20 minutes daily over 20 days can reduce migraine pain. About 60 people with chronic migraine will receive either real or sham stimulation, and 20 people with episodic migraine will be observed for comparison. The goal is to see if this treatment can safely decrease the number of severe headache days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female, aged 18 to 65 (inclusive) * Patients must have Episodic migraines that started before the age of 50, and currently experience: * Chronic migraine (ICHD-3-beta), headache occurring on 15 days/month for more than six months, which, on at least eight days/month, has the features of a migraine headache. * Episodic migraine (low frequency), specifically those with headache occurring less than 8 days/month. * Willing to limit the introduction of new treatments and medications during the study period. Exclusion Criteria: * Significantly greater pain in body sites other than the head * Active, untreated major concurrent systemic illness other than migraine * Medical conditions that can impair health status independent of migraine (including cardiopulmonary disorders, malignancy, uncontrolled endocrine or allergies) * Systemic rheumatic disorders (i.e., rheumatoid arthritis, systemic lupus erythematosus, gout, and fibromyalgia); * History or current evidence of a psychotic disorder (e.g., bipolar disorder, schizophrenia) or severe major depression, as evidenced by Beck Depression score of \>30\* * History of neurological disorder (e.g., epilepsy, stroke, neuropathy, neuropathic pain) * Medication overuse headache (ICHD-3), regular intake for ≥10 days per month of ergotamine, triptans, combination analgesics, or any combination thereof OR ≥15 days per month of simple analgesics (acetaminophen, aspirin, NSAID), for more than 3 months * Current use of opioid or dopaminergic drugs (or use within the last 3 months) or substance abuse (self-reported) * Drug test positive for opioid or recreational drug (e.g., cannabis) at the time of the PET scan visits * Allergic response to study radiotracers or chemically related drugs * Excluded by MRI Center or PET Center safety screening checklist (as administered by study staff) * Pregnant or lactating (negative urine pregnancy test must be available before any PET procedures are initiated) * Prior use of tDCS
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic migraine are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can freezing nerves stop chronic migraine pain?
- Could an inhaled sedative quiet the Brain's migraine alarm?
- Can neck exercises turn down the volume on chronic migraine?
- Can a No-Fridge migraine shot replace botox?
- Could a common cholesterol drug stop chronic migraine?
- Migraine relief may sharpen the mind: study investigates cognitive benefits of preventive therapies